Results 201 to 210 of about 6,859 (228)

Single Nucleotide <i>SMN1</i> Variants in a Cohort of Individuals With Spinal Muscular Atrophy. [PDF]

Neurol Genet
Rimoldi M, Magri F, Meneri M, Gagliardi D, Ada Sansone V, Albamonte E, Ottoboni L, Comi GP, Mercuri E, Tiziano FD, Ronchi D, Corti S.   +11 more
europepmc   +1 more source

Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment. [PDF]

J Neurol
Asteggiano C, Mazzocchi L, Farina L, Paoletti M, Barzaghi L, Caverzasi E, Parravicini S, Dainesi MI, Gardani A, Savini G, Bergsland N, Ballante E, Wheeler-Kingshott CAMG, Berardinelli A, Pichiecchio A.   +14 more
europepmc   +1 more source

A cost-utility analysis of newborn screening for spinal muscular atrophy in Canada. [PDF]

Orphanet J Rare Dis
Pace A, Roda W, Poon C, McMillan HJ, Oskoui M, MacKenzie A, Chakraborty P, Round J.   +7 more
europepmc   +1 more source

Enhancing the effects of nusinersen with cybernic treatment using Hybrid Assistive Limb (HAL) in spinal muscular atrophy: a real-world case series and exploratory cohort analysis. [PDF]

Orphanet J Rare Dis
Nakajima T, Saito T, Hashiguchi A, Nakabayashi T, Kodera K, Utsumi K, Kanayama T, Urabe H, Kinoshita S.   +8 more
europepmc   +1 more source

Rehabilitation improves the effectiveness of nusinersen in children with type 2 spinal muscular atrophy: pNF-H and muscle MRI as potential biomarkers. [PDF]

Front Neurol
Sun Y, Li W, Cui X, Li Y, Gao X, Fu D, Zhao X, Cao T, Zhu M.   +8 more
europepmc   +1 more source

Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial. [PDF]

BMJ Open
Zhang J, Wang B, He J, Zhu L, Dong X.
europepmc   +1 more source

Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. [PDF]

Eur J Neurol
Coratti G, Bovis F, Pane M, Pasternak A, Albamonte E, Mizzoni I, Glanzman AM, Morando S, Montes J, Cavallina I, Dunaway Young S, Duong T, Rolle E, Civitello M, De Sanctis R, Bravetti C, Ricci F, Gadaleta G, Mongini T, Sframeli M, Pera MC, Messina S, D'Amico A, Catteruccia M, Brolatti N, Hirano M, Zolkipli-Cunningham Z, Darras BT, Bertini E, Bruno C, Day J, Sansone VA, Finkel RS, Mercuri E, iSMAC/international SMA consortium.   +34 more
europepmc   +1 more source

Nusinersen for spinal muscular atrophy.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Laboratory monitoring of nusinersen safety

Muscle & Nerve, 2021
AbstractIntroductionThis retrospective study reports our tertiary care center's experience with intrathecal nusinersen administration in children and adults with spinal muscular atrophy (SMA).MethodsWe reviewed safety monitoring laboratory results and need for procedural sedation and fluoroscopy‐guidance in all SMA patients receiving nusinersen between
Natalie L, Goedeker, Jennifer L, Gibbons, Arun S, Varadhachary, Anne M, Connolly, Craig M, Zaidman   +4 more
openaire   +2 more sources